Identifying patients with high risk stage I NSCLC using tumor-informed plasma ctDNA - PubMed
3 hours ago
- #NSCLC
- #ctDNA
- #prognostic
- Circulating tumor DNA (ctDNA) is a significant prognostic factor in cancer patients.
- A study of 153 clinical stage I NSCLC patients used tumor-informed plasma ctDNA testing (RaDaR™) to assess recurrence risk.
- Pre-operative ctDNA was detected in 22.4% of patients and was linked to worse recurrence-free survival (RFS).
- No post-operative ctDNA was detected in patients with pathologic stage I disease.
- The 2-year RFS was 84.2%, but lower (69.1%) in patients with pre-operative ctDNA detected.
- Preoperative ctDNA detection and invasive tumor size were independently associated with RFS in pathologic stage I NSCLC.
- The study supports the use of plasma ctDNA for treatment decision-making in stage I NSCLC.